ED
STSA

Exane Derivatives’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Exane Derivatives’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,078
Closed -$15.9K – 874
2020
Q3 		$15.9K Sell
4,078
-70
-2% -$1.41K ﹤0.01% 454
2020
Q2 		$119K Hold
4,148
– – 0.03% 272
2020
Q1 		$89.3K Buy
+4,148
New +$94.2K 0.02% 294

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Exane Derivatives's STSA Position: Q4 2020 in Review

Exane Derivatives sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2020, closing a stake of 4,078 shares — an estimated $15.9K sold.

Exane Derivatives first reported a position in STSA in Q1 2020 and held it in 3 quarters. The position peaked at $119K in Q2 2020. 48 funds tracked by Wall St. Rank hold STSA as of Q4 2020.

  • Exane Derivatives reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Exane Derivatives sold 4,078 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $15.9K.
  • Exane Derivatives first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
  • Exane Derivatives's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $119K in Q2 2020.
  • 48 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on Exane Derivatives's 13F filing for Q4 2020, filed 27 Jan 2021.